Clinical trial registry record

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 14, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04894071
Last registry update
January 14, 2022
Status
Completed
Phase
Phase 1
Sponsor
Smilebiotek Zhuhai Limited
Enrollment
69
Countries
United States
Match confidence
70%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
69
Population
ALL · 18 Years to 75 Years
Duration
2021-05-17 to 2021-11-15
Intervention
QA102; Placebo
Comparator
Placebo group
Outcomes measured
Incidence and severity of Adverse Events — Up to 7 days after dosing; Area under the plasma concentration-time curve (AUC) from time zero to 12 hours postdose [AUC0-12] — up to 12 hours pos…; Maximum observed plasma concentration [Cmax] — Up to 48 hours postdose; time of the maximum observed plasma concentration [tmax] — up to 48 hours postdose
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 70% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 70%Source terminology contains: age-related macular degeneration. Title supplies longevity context: older adult. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON